CNCE News and Press, Concert Pharmaceuticals Inc. From 11/07/22

Concert Pharma ( NASDAQ: CNCE ) stock fell sharply on Monday despite the biopharma reporting a loss lighter than expected for third quarter. The Lexington-based drug developer focused on the treatment of autoimmune diseases reported a loss of $0.58 per share, notching ...

Concert Pharmaceuticals, Inc. (CNCE) Q3 2022 Earnings Conference Call November 07, 2022, 8:30 AM ET Company Participants Justine Koenigsberg - Senior Vice President, Corporate Communications and Investor Relation Roger Tung - President and Chief Executive Officer ...

Concert Pharma press release ( NASDAQ: CNCE ): Q3 GAAP EPS of -$0.58 beats by $0.01 . Revenue of $0.08M (-84.0% Y/Y) in-line. Cash, cash equivalents and investments as of September 30, 2022 totaled $148.9 million, compared to $141.6 million as of December 31, 2021....

Company Plans to Submit NDA in First Half of 2023 for Deuruxolitinib in Adults with Moderate to Severe Alopecia Areata Deuruxolitinib (CTP-543) Phase 3 Data Presented at the EADV Congress Late Breaking News Session Additional Deuruxolitinib Phase 3 Results to...

Concert Pharma ( NASDAQ: CNCE ) is scheduled to announce Q3 earnings results on Monday, November 7th, before market open. The consensus EPS Estimate is -$0.59 and the consensus Revenue Estimate is $0.08M (-84.0% Y/Y). Over the last 3 months, EPS estimates have seen 4 ...

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss i...

35 Percent of Patients Treated With CTP-543 12 mg Twice-Daily Achieved At Least 90 Percent Scalp Hair Coverage (SALT Score ≤ 10) After 24 Weeks of Treatment Newly-Reported Results Show Significant Improvement in Eyebrow and Eyelash Regrowth in Patients Treated With Both...

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022. The on-demand webcast of the p...

September is Alopecia Areata Awareness Month Alopecia Areata is a Serious Autoimmune Disorder with Limited Treatment Options In recognition of Alopecia Areata Awareness Month, bridges, buildings and other landmarks across the United States will be illuminated...

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that results from the first Phase 3 clinical trial of CTP-543 (THRIVE-AA1) in adult patients with moderate to severe alopecia areata will be presented as a late breaking oral presentation at the 31 st European Academy ...